SecBot SecBot
8-K ·Filed Jun 29, 2026

TARA

Protara Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001213900-26-073184
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor for any further C-suite departures or delays in clinical development timelines. The internal absorption of CMO duties suggests continuity, but the lack of a named replacement could signal organizational flux.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.82
T+0 close · Jun 29, 2026 · via day close
Latest settled
−7.33%
T+60 · $3.54
Vs SPY
−10.15%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 30 $3.82entry
  2. T+1 · 5mo ago +5.76%α +5.89% · $4.04
  3. T+5 · 4mo ago +6.81%α +6.20% · $4.08
  4. T+20 · 4mo ago +5.76%α +6.79% · $4.04
  5. T+60 · 8w ago −7.33%α −10.15% · $3.54
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Protara Therapeutics disclosed the resignation of Chief Medical Officer Leonardo Viana Nicacio, M.D., effective June 26, 2026, to pursue other opportunities. His responsibilities will be absorbed by existing clinical leadership, including Carla Beckham, M.D. and Jacqueline Zummo, Ph.D. This is a routine officer departure with no immediate financial or operational impact.

Key Facts

  • Chief Medical Officer Leonardo Viana Nicacio resigned effective June 26, 2026 to explore other opportunities.
  • Duties will be subsumed by Lead Medical Director Carla Beckham, M.D. under oversight of Chief R&D Officer Jacqueline Zummo, Ph.D.
  • No replacement CMO has been named; no compensation or employment agreement details were disclosed.

Financial Impact

No financial impact disclosed.

Risk Factors

  • Potential disruption to clinical development programs if the departing CMO was a key driver.
  • Further executive departures could signal broader organizational instability.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-073184
Document: 0001213900-26-073184-index-headers.html0001213900-26-073184
Document: 0001213900-26-073184-index.html0001213900-26-073184
Document: 0001213900-26-073184.txt0001213900-26-073184

Track record

13 reports on TARA

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +17.50% at T+60 after the May 26, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.52 Now $2.38 +5.56% settles Feb 12
  2. Nov 6, 202610d ago 8-K Neutral 4/10 No price data
  3. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $2.30 Now $2.38 +3.48% settles Feb 4
  4. Oct 15, 20264w ago Press Release Neutral 3/10 Entry $2.40 Now $2.38 −0.83% settles Jan 12
  5. Aug 11, 202613w ago 8-K Neutral 4/10 No price data
  6. Aug 11, 202613w ago Press Release Neutral 4/10 Entry $3.91 to $2.35 Now $2.38 −39.13% ▼ −39.90% −39.41% vs SPY
  7. Jun 29, 202620w ago 8-K Neutral 2/10 Viewing Entry $3.82 to $3.54 Now $2.38 −37.70% ▼ −7.33% −10.15% vs SPY
  8. May 26, 202625w ago EFFECT Bearish 5/10 Entry $4.80 to $3.96 Now $2.38 +50.42% ▲ +17.50% +20.22% vs SPY
  9. May 15, 202626w ago Press Release Bullish 7/10 Entry $5.10 to $3.91 Now $2.38 −53.33% ▼ −23.33% −27.85% vs SPY
  10. May 13, 202626w ago 8-K Neutral 4/10 No price data
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 29, 2026